SCHOTT Pharma (1SXP) investor relations material

Executive summary

• Q3 2026 revenue reached EUR 282 million, up 8.3% at constant currencies, with nine-month revenue at EUR 769.8 million to EUR 770 million, driven by strong demand for high-value solutions and DCS products.

• Q3 EBITDA was EUR 75 million (26.8% margin); nine-month EBITDA was EUR 205.3 million, down 3.8% year-on-year, with margin at 26.7%.

• HVS revenue share reached 59% in Q3, supporting margin expansion and aligning with midterm targets.

• Strategic focus on innovation, capacity expansion in the U.S., Hungary, and Switzerland, and partnerships, including Nemera collaboration and new customer agreements.

• Profit for nine months was EUR 103.4 million, with EPS at EUR 0.68, both down year-on-year.

Financial highlights

• Q3 group revenues were EUR 281.8 million, up 8.3% at constant currencies; nine-month revenues were EUR 769.8 million to EUR 770 million, up 4.1%-4.4% year-on-year.

• Q3 EBITDA was EUR 75 million (26.8% margin); nine-month EBITDA was EUR 205.3 million (26.7% margin), down 3.8% year-on-year.

• EBIT for nine months was EUR 139.7 million, down 10.4% year-on-year, mainly due to higher depreciation.

• Free cash flow improved 49% year-on-year, reported as EUR 58.9 million and EUR 141 million in different sources.

• Net income for nine months was EUR 103.4 million; EPS at EUR 0.68, down 9%-9.3% year-on-year.

Outlook and guidance

• Full-year 2026 revenue growth guidance raised to 5%-6% at constant currencies; EBITDA margin expected at 27%-28%.

• Q4 revenue growth expected to accelerate, with DDS segment contributing above Q3 levels; DCS is seasonally weaker.

• HVS revenue share expected to remain at 57%-59% for the full year.

• One-off revenue of around EUR 15 million in Q4 from a new glass syringe customer agreement is included in guidance and will be a headwind for 2027.

• Guidance assumes stable exchange rates and no major geopolitical or supply chain disruptions.